OverviewSuggest Edit

Lyra Therapeutics (formerly known as 480 Biomedical) is a therapeutics company focused on the development of integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It develops LYR-210 and LYR-220, bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis. The company offers XTreo designed to enable sustained delivery of medications for many months of therapy, targeting tissues deep in the ENT passages and potentially other diseased tissues that are not accessible with conventional therapeutic approaches.

TypePublic
Founded2005
HQWatertown, MA, US
Websitelyratherapeutics.com

Latest Updates

Employees (est.) (Mar 2020)34
Job Openings8
Share Price (Oct 2021)$7.8(-1%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Lyra Therapeutics

Maria Palasis

Maria Palasis

President and Chief Executive Officer, Director
Corinne Noyes

Corinne Noyes

Senior Vice President of Commercial Strategy & Market Development
Robert Kern

Robert Kern

Chief Medical Officer
Vineeta Belanger

Vineeta Belanger

Senior Vice President, Clinical Affairs
Danny Concagh

Danny Concagh

Senior Director, Chemistry and Manufacturing
Pamela Nelson

Pamela Nelson

Senior Vice President of Regulatory Affairs
Show more

Lyra Therapeutics Office Locations

Lyra Therapeutics has an office in Watertown
Watertown, MA, US (HQ)
480 Arsenal St
Show all (1)

Lyra Therapeutics Financials and Metrics

Lyra Therapeutics Revenue

USD

Net income (Q1, 2021)

(7.8m)

EBIT (Q1, 2021)

(7.8m)

Market capitalization (22-Oct-2021)

101.9m

Closing stock price (22-Oct-2021)

7.8

Cash (31-Mar-2021)

66.1m

EV

38.0m
Lyra Therapeutics's current market capitalization is $101.9 m.
Annual
USDFY, 2020

General and administrative expense

9.7m

R&D expense

12.5m

Operating expense total

22.2m

EBIT

(22.2m)
Quarterly
USDQ1, 2020Q2, 2020Q1, 2021

General and administrative expense

1.3m2.4m3.1m

R&D expense

3.0m2.1m4.8m

Operating expense total

4.2m4.5m7.8m

EBIT

(4.2m)(4.5m)(7.8m)
Annual
USDFY, 2020

Cash

74.6m

Prepaid Expenses

1.3m

Current Assets

75.9m

PP&E

2.2m
Quarterly
USDQ1, 2020Q2, 2020Q1, 2021

Cash

35.2m86.6m66.1m

Prepaid Expenses

293.0k2.7m1.2m

Current Assets

35.5m89.3m67.4m

PP&E

284.0k329.0k3.2m
Annual
USDFY, 2020

Net Income

(22.1m)

Depreciation and Amortization

95.0k

Accounts Payable

345.0k

Cash From Operating Activities

(21.1m)
Quarterly
USDQ1, 2020Q2, 2020Q1, 2021

Net Income

(4.2m)(8.8m)(7.8m)

Depreciation and Amortization

8.0k21.0k70.0k

Accounts Payable

432.0k138.0k452.0k

Cash From Operating Activities

(4.0m)(11.5m)(7.6m)
USDQ1, 2020

Financial Leverage

-0.3 x
Show all financial metrics

Lyra Therapeutics Online and Social Media Presence

Embed Graph

Lyra Therapeutics News and Updates

Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology

LYR-210 is the First Drug-Eluting Product Candidate to Demonstrate Statistically Significant Symptom Improvement for Six Months with a Single Administration in Surgically Naïve Chronic Rhinosinusitis Patients

Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data

LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS

Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer

Seasoned investment banking executive brings extensive finance, partnering and M&A experience to the role Seasoned investment banking executive brings extensive finance, partnering and M&A experience to the role

Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other disease…

Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31

WATERTOWN, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased…

Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference

WATERTOWN, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased…
Show more

Lyra Therapeutics Blogs

Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts

Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts Paul.alfano@na… Tue, 10/19/2021 - 07:23 Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts …

Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society

Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society Content Import Mon, 10/04/2021 - 07:04 Lyra Therapeutics Presents New Positive Phase 2…

Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy

Results demonstrate XTreo ™ technology platform provides targeted and sustained dosing of anti-inflammatory medication Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-210, currently poised to enter Phase 3

Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments

Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments Content Import Mon, 08/09/2021 - 16:05 Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments August 9, 2021 T…

Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9

WATERTOWN, Mass. , July 26, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis

Single primary endpoint defined as three cardinal symptoms at 24 weeks Company to host conference call at 5:00 PM ET today WATERTOWN, Mass. --(BUSINESS WIRE)--Jun. 8, 2021-- Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to
Show more

Lyra Therapeutics Frequently Asked Questions

  • When was Lyra Therapeutics founded?

    Lyra Therapeutics was founded in 2005.

  • Who are Lyra Therapeutics key executives?

    Lyra Therapeutics's key executives are Maria Palasis, Corinne Noyes and Robert Kern.

  • How many employees does Lyra Therapeutics have?

    Lyra Therapeutics has 34 employees.

  • Who are Lyra Therapeutics competitors?

    Competitors of Lyra Therapeutics include Intersect ENT, Wugen and oncomed.

  • Where is Lyra Therapeutics headquarters?

    Lyra Therapeutics headquarters is located at 480 Arsenal St, Watertown.

  • Where are Lyra Therapeutics offices?

    Lyra Therapeutics has an office in Watertown.

  • How many offices does Lyra Therapeutics have?

    Lyra Therapeutics has 1 office.